Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

Probably the biggest objection to buying Lilly stock is its valuation. The big pharmaceutical company's shares trade at nearly 37.5 times forward earnings. Does this high multiple disqualify Lilly as ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Eli Lilly & Co. reported its results for the third quarter of 2024, with revenue up 20% y/y but failing to meet market ...

The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.

Eli Lilly's EBGLYSS has demonstrated improvement in skin condition and itch relief in patients with moderate-to-severe atopic dermatitis, according to new results from the Phase IIIb ADapt study.

David Risinger’s rating is based on the promising topline data from Eli Lilly’s Phase 3b ADapt trial, which showcased the effectiveness of Ebglyss (lebrikizumab) for patients with moderate-to ...

Lilly scored another big win back in September when the FDA approved its eczema drug, Ebglyss. Although I suspect Lilly will face more competition in the eczema market than it will in Alzheimer's ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced that its drug EBGLYSS, an interleukin-13 (IL-13) inhibitor, has shown to improve skin condition and reduce itchiness in patients with ...

Eli Lilly (NYSE:LLY) said that in patients with moderate-to-severe atopic dermatitis who had previously been treated with dupilumab, known by its brand name Dupixent, their Phase 3b study showed the ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...